Key facts
- This page summarizes Neil Kumar's Form 3 filing for BridgeBio Oncology Therapeutics, Inc. (HLXB).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Aug 2025, 17:13.
Neil Kumar - 11 Aug 2025 Form 3 Insider Report for BridgeBio Oncology Therapeutics, Inc. (HLXB)
- Reporting relationship
- Director
- Issuer ticker
- HLXB
- Reported as of
- 11 Aug 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 18 Aug 2025, 17:13:01 UTC
- Prior SEC filing
- 11 Aug 2025
- Next SEC filing
- 19 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Aaron Chan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Neil Kumar filed Form 3 for BridgeBio Oncology Therapeutics, Inc. (HLXB) on 18 Aug 2025.
Change
- Previous filing in this sequence was filed on 11 Aug 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001742485
Primary reporting owner
Kumar Neil
- Relationship
- Director
- Address
- BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
- Signature
- /s/ Aaron Chan, Attorney-in-Fact
- Signature date
- 18 Aug 2025
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.
SEC remarks
Exhibit 24 - Power of Attorney